YOLFTbeta
Anatara Lifesciences Ltd

Anatara Lifesciences Ltd

ANR · AU · Healthcare / Biotechnology

0.008AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.008
Open0.008
Day Range0.008 – 0.008
52-Week Range0.008 – 0.017
Volume560.30K
Market Cap2.85M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.00%
Beta0.69
50-Day Avg0.0093
200-Day Avg0.0102

About

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include irritable bowel syndrome; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral complementary medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. David Lionel Brookes F.A.C.I.D., FACRRM, FAICD, MBBS
  • Employees0
  • Headquarters81 Flinders Street, Adelaide, SA, Australia, 5000, Australia
  • Websitehttps://anataralifesciences.com

Leadership

  • Dr. David Lionel Brookes F.A.C.I.D., FACRRM, FAICD, MBBSExecutive Chairman & MD · b. 1960
  • Mr. Jonathan LindhCompany Secretary
  • Ms. Hayley van der Meer B Biomed Sc, Grad Dip Marketing ManagementCommercial Manager

Financials

Income Statement

Currency: AUD2011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue-110.00K90.00K90.00K202.29K2.45M2.85M6.47K663.40K000-644.03K969.46K-
Growth (%)---18.18%0.00%+124.77%+1110.31%+16.56%-99.77%+10158.31%-100.00%----+50.53%-
Cost of Revenue-185.00K170.91K256.12K213.56K878.86K1.26M785.93K776.26K16.10K6.26K24.68K24.76K748.91K1.60M84
Gross Profit---80.91K-166.12K-152.18K1.57M1.59M-779.46K-112.85K-16.10K-6.26K-24.68K-24.76K-748.91K-633.97K-84
Gross Margin---89.90%-184.57%-75.23%64.10%55.70%-12052.95%-17.01%-----116.29%-65.39%-
Operating Expense--105.41K709.18K1.85M2.58M3.51M3.01M2.90M4.19M3.11M3.00M3.26M710.22K1.32M1.25M
Operating Income---186.33K-875.29K-2.00M-1.01M-1.92M-3.79M-3.01M-4.21M-3.11M-3.02M-3.28M-1.46M-1.96M-1.25M
Operating Margin---207.03%-972.55%-987.45%-41.09%-67.38%-58595.45%-453.84%-----226.56%-201.83%-
EBITDA--93212.44K1.68K-1.23M-4.22M-4.71M-3.69M-4.01M-3.01M-2.97M-3.21M-1.46M-1.96M-1.25M
EBITDA Margin--1.04%13.82%0.83%-50.08%-147.86%-72838.33%-555.69%-----226.18%-201.76%-
Net Income---185.39K-862.86K-1.80M-723.93K-1.71M-3.57M-2.87M-3.36M-2.00M-2.53M-2.02M-1.45M-1.95M-933.23K
Net Income Margin---205.99%-958.73%-887.45%-29.57%-59.75%-55188.12%-432.36%-----225.34%-201.63%-
R&D-145.00K130.92K177.44K128.67K735.07K1.12M785.93K776.26K1.29M840.82K747.18K1.60M748.91K1.60M280.50K
R&D as % of Total Revenue-131.82%145.47%197.15%63.61%30.02%39.33%12152.95%117.01%----116.29%165.39%-
Interest Expense00000000003003.32K2.37K-7.42K3.07K
Interest Expense % of Total Revenue-0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-----0.77%-

Balance Sheet

Currency: AUD2011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets4.00K50.00K72.30K7.45M5.63M13.92M12.32M9.81M6.38M3.34M4.33M1.77M1.42M1.67M1.15M820.39K
Total Liabilities20.00K146.00K352.96K227.62K146.98K444.62K295.44K1.22M466.76K486.96K496.67K403.35K494.83K306.85K612.42K108.86K
Total Equity---280.65K7.23M5.48M13.48M12.02M8.59M5.92M2.86M3.83M1.36M924.54K1.36M535.97K711.54K
Cash3.00K43.00K66.02K7.45M1.50M6.39M8.77M1.45M1.36M2.68M3.43M1.12M351.18K982.11K101.36K470.92K
Total Debt--345.96K------79.92K79.92K65.81K--407.42K-
Net Debt--279.94K-7.45M-1.50M-6.39M-8.77M-1.45M-1.36M-2.68M-3.35M-1.05M-351.18K-982.11K306.06K-470.92K

Cash Flow

Currency: AUD2011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow---177.22K-639.27K-1.92M-280.37K-2.88M-3.32M-2.24M-2.72M-2.10M-2.23M-2.26M-1.25M-2.27M-339.24K
Investing Cash Flow----4.08M-4.08M-3.31M5.26M-4.00M2.15M4.05M-3.98K-56.56K-1.73K50.00K--
Financing Cash Flow22.00K126.00K200.30K1.62M6.45M8.48M02.85M2.85M2.85M2.85M-22.44K1.49M1.83M1.39M708.80K
Capital Expenditure00024.78K24.78K6.61K41.61K23.17K4.08K4.08K3.98K6.56K1.73K430
Free Cash Flow---177.22K-639.27K-1.95M-286.97K-2.92M-3.34M-2.24M-2.73M-2.10M-2.24M-2.26M-1.25M-2.27M-339.24K
Dividends Paid-----00---2.81M27.44K1.30M---
FCF to OCF--100.00%100.00%101.29%102.36%101.45%100.70%100.00%100.15%100.19%100.29%100.08%100.00%100.00%100.00%
Dividend Paid to FCF-----0.00%0.00%----133.88%-1.23%-57.62%---

Earnings

Report DateFeb 23, 2016Aug 30, 2016Feb 23, 2017Sep 28, 2017Feb 22, 2018Aug 31, 2018Feb 19, 2019Aug 26, 2019Feb 25, 2020Aug 24, 2020Feb 23, 2021Aug 24, 2021Feb 23, 2022Aug 29, 2022Feb 24, 2023Feb 24, 2025Aug 13, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.00----0.000.00
EPS Actual-0.030.01-0.01-0.03-0.03-0.04-0.04-0.02-0.04-0.03-0.02-0.02-0.02-0.02-0.01-0.010.00
Surprise-----------------
Timing------------After-hoursAfter-hoursAfter-hours--

Key Statistics & Ratios

Market Cap2.85M
Enterprise Value3.15M
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.94
Price / Book4.00
EPS0.00
Book Value0.002
Revenue (TTM)318.40K
Gross Profit (TTM)37.90K
EBITDA-935.02K
Profit Margin-293.10%
Operating Margin-299.81%
Return on Equity-149.62%
Return on Assets-59.37%
Shares Outstanding316.31M
Shares Float211.13M
Beta0.69
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%